Interpace Biosciences Unveils Innovative Results at ATA Meeting
Highlights from the Meeting
At a recent gathering, insightful findings were shared regarding the benefits of using archival cytology slides in molecular testing. This allows successful outcomes even in cases that previously lacked sufficient testing results through other established molecular diagnostic platforms. The aim is to potentially reduce the need for repeated fine-needle aspirations (FNAs) through these findings.
The analysis involving 28,144 samples provided a clearer understanding of how ThyGeNEXT and ThyraMIRv2 work together to refine risk assessments for Bethesda III/IV thyroid nodules, especially within the RAS-like and mutation-negative categories.
Presentations and Key Findings
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) showcased two pivotal posters during the important event. The first work presented, titled “Utilizing Archival Cytology Slides to Overcome Molecular Testing Insufficiency Rates in Cytologically Indeterminate Thyroid Nodules: An Institutional Experience,” detailed a quality-improvement initiative led by Dr. Temma Kaufman from Associated Pathologists PA, BayCare St. Joseph’s Hospital. In this initiative, 65 thyroid fine-needle aspiration cases, initially categorized as insufficient for testing by another method, showed successful molecular results in 56 cases (approximately 86%) using Interpace’s advanced testing processes. This represents a significant step towards reducing repeat FNAs and optimizing operational workflows.
The second presentation titled “Refined Risk Stratification of Bethesda III/IV Thyroid Nodules Using ThyGeNEXT and ThyraMIRv2” reflected outcomes from cases thoroughly analyzed. This study observed the identification rates of specific alterations such as BRAF V600E-like and RAS-like mutations, offering a clearer view on how tests can stratify malignancy risk effectively. With ThyraMIRv2 further characterizing outcomes within these groups, clinicians are equipped to make more precise decisions regarding patient management.
The Impact on Clinical Decision-Making
Dr. Tom Burnell, President & CEO of Interpace Biosciences, expressed enthusiasm for the findings. He commented, “These data continue to validate the real-world utility of our combination platform. It highlights that using archival cytology slides not only facilitates better testing outcomes but also significantly enhances clinical workflow, aiding in the decision-making process for patients.”
Dr. Temma Kaufman also emphasized the meaningful changes brought about by adopting this testing platform, noting the ability to derive actionable molecular results from cases that would have otherwise required repeated procedures. This development provides clearer guidance in the management and care of patients.
About Interpace Biosciences and Its Innovative Approaches
Interpace’s approach integrates next-generation DNA/RNA mutation analysis with microRNA pairwise expression profiling, redefining how malignancy risks are assessed in thyroid nodules. This platform stands out particularly in cases that are RAS-like or mutation-negative, as it enables healthcare professionals to make better-informed clinical decisions.
Interpace Biosciences is positioning itself as a frontrunner in individualized medicine, offering services across various stages of the therapeutic process—from diagnosis through to treatment applications. Their clinical services focus on delivering relevant molecular diagnostic tests along with bioinformatics insights and pathology assistance that aid in cancer risk evaluation.
The company boasts two primary commercialized molecular tests, ThyGeNEXT, aimed at diagnosing thyroid cancer from nodules via advanced sequencing, and ThyraMIRv2, which utilizes microRNA analysis to enhance diagnostic accuracy. The combination of these tests creates a robust framework that improves the reliability of cancer assessments.
For additional information about Interpace Biosciences and its innovative solutions, interested individuals can visit the official website at www.interpace.com.
Frequently Asked Questions
What were the main findings presented by Interpace Biosciences at the ATA meeting?
Interpace Biosciences demonstrated successful results using archival cytology slides to enhance molecular testing outcomes and refined risk assessments for thyroid nodules.
How effective is the ThyGeNEXT and ThyraMIRv2 testing combination?
The testing combination proved effective, showing considerable success in identifying mutations and stratifying risks in indeterminate thyroid nodules.
What is the significance of using archival cytology slides?
Using archival slides enabled the company to obtain successful molecular results in cases that would otherwise have been deemed insufficient, improving patient management.
What services does Interpace Biosciences offer?
Interpace provides clinical diagnostic tests, bioinformatics, and pathology services focused on cancer risk assessment and personalized medicine approaches.
How can patients and healthcare professionals learn more about Interpace Biosciences?
More information can be found on their official website, which offers comprehensive details about their services and innovative testing solutions.
